Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Stent Technologies Inc.

Division of Boston Scientific Corp.
www.advancedstent.com

Latest From Advanced Stent Technologies Inc.

Israel's Device Community: Opportunities and Challenges Ahead

This article is excerpted from "Israel's Device Community: Finding New Models as Medtech Matures," In Vivo, October 2008. (Article number 2008800161.)
Middle East and Africa

Stent Recap: Turmoil in 2007--What's Ahead for Interventional Cardiology?

Although safety concerns about drug-eluting stents have been mitigated somewhat by recent reports of more positive clinical data, there is lingering unease and confusion in the cardiology community about when, how, and in whom to use these devices. There is also a growing wave of healthy skepticism about the way stent trials are designed and conducted, and whether evidence- based medicine is well served by the current process.
Medical Device

Cappella Inc.

Of the more than one million percutaneous coronary interventions performed in the US last year, approximately 20% of cases involved bifurcations. Even with the advent of drug-eluting stents (DES) as well as dedicated bifurcation stenting systems and creative stenting techniques, lesion histology, patient anatomy, and equipment limitations have frequently led to suboptimal results. Cappella was founded with the goal of improving outcomes in patients with bifurcated lesions.
Medical Device Platform Technologies

AngioScore Inc.

A great deal of occlusive disease cannot be treated with stents and conventional angioplasty balloons. Some 30% of lesions are complex and require special methods or tools because they're hard and calcified, because the lesions are ostial or located at bifurcations, because they're in vessels prone to elastic recoil, because disease is long and diffuse, or because they are otherwise unstentable. It is exactly this set of challenges that AngioScore has set out to address.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Boston Scientific Corp.
  • Senior Management
  • Noam C Mizrahi, CEO
    Merrill Weber, Pres.
    Eric Williams, VP, R&D
    Ilana Odess, EVP, Mktg. & Sales
  • Contact Info
  • Advanced Stent Technologies Inc.
    Phone: (925) 931-9990
    6900 Koll Center Dr., Ste. 415
    Pleasanton , CA 94566
    USA
UsernamePublicRestriction

Register